Appointment of Non-Executive Director
Proteome Sciences plc (AIM:PRM) is pleased to announce the appointment of Helen Spice FCA as an independent non-executive director of the Company, with immediate effect.
Interim results for the six months ended 30 June 2026
Proteome Sciences announces its unaudited interim results for the six months ended 30 June 2026 (“H1 2026”).
Further GCLP Chemoproteomics contract secured
As initially announced in June this year, Proteome Sciences plc (AIM:PRM) is pleased to now confirm that the Company has secured the expected significant clinical contract for its chemoproteomics platform. This project has been developed to comply with Good Clinical Laboratory Practice (“GCLP”) accreditation and will be undertaken at our laboratories in Frankfurt, Germany.
Target engagement/chemoproteomics contract
Proteome Sciences plc (AIM:PRM) is pleased to announce that the Company has secured a further significant clinical contract connected to its target engagement/chemoproteomics platform.
Result of Annual General Meeting (AGM)
The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 12.00 noon today, all resolutions were duly passed.
Final results for the year ended 31 December 2025
The Company is pleased to announce its audited results for the year ended 31 December 2025.